Targeted pill to skip chemo for high-risk breast cancer
Part of Cancer, Skin clinical trials.
This trial tests whether adding a targeted pill (dalpiciclib) to standard hormone therapy can safely replace chemotherapy for women with small, hormone-positive, high-risk breast cancers.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between 18 and 70 years old.
- Your breast cancer is small (0.5 to 2 cm), has not spread to lymph nodes, is ER-positive (≥50%) and HER2-negative.
- Your tumor has at least one high-risk feature: very fast growth (Ki-67 ≥50%), Grade 3, a high-risk gene test, or you are 40 or younger.
- You have good organ function (normal blood counts, liver, and kidney tests) and an ECOG performance score of 0 or 1.
- You have not received any cancer treatment before surgery (like chemo, radiation, or hormone therapy) and the cancer has not spread beyond the breast.
- You are not pregnant or breastfeeding, and you agree to use effective birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if adding a targeted drug (CDK4/6 inhibitor) to hormone therapy works better than hormone therapy alone for women with a certain type of breast cancer (HR+/HER2-). The study measures the activity of tumor cells (Ki-67) to help decide treatment.
This trial tests whether it is safe to skip chemotherapy after surgery for certain patients with early-stage, hormone-receptor positive, HER2-negative breast cancer that has not spread to lymph nodes. Instead, they would receive hormone therapy plus a targeted CDK4/6 inhibitor (a pill that blocks cancer cell growth).
This study compares taking a daily pill (dalpiciclib with hormone therapy) versus standard chemotherapy before breast cancer surgery. It's for postmenopausal women with a common type of early breast cancer that is strongly hormone-receptor positive and HER2-negative.
This trial tests if women with a common type of breast cancer (HR+/HER2-) can safely skip chemotherapy after surgery by taking targeted medication (ribociclib) plus hormone therapy. A special blood test called ctDNA helps doctors decide if chemo isn't needed.
This trial tests a new combination of oral hormone therapy (an aromatase inhibitor) plus a CDK4/6 inhibitor (dalpiciclib) for women with early-stage but locally advanced (Stage II–III) hormone receptor-positive, HER2-negative breast cancer. The goal is to shrink the tumor before surgery, potentially improving outcomes.
This trial tests whether a combination of two pills (dalpiciclib and letrozole) can help maintain control of hormone-receptor-positive, HER2-negative breast cancer after initial chemotherapy. It is for people whose cancer has spread or returned and who have not been on an oral CDK4/6 inhibitor before.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.